{"entity":{"id":"nst-628","kind":"drug","name":"NST-628","aka":[],"tldr":"NST-628 is an experimental oral small-molecule molecular glue from Nested Therapeutics, in phase 1 trials for MAPK pathway-mutated or -dependent advanced solid tumours, melanoma and non-small cell lung cancer and other cancers.","summary":"NST-628 is an oral small-molecule molecular glue from Nested Therapeutics. A non-degrading, fully brain-penetrant pan-RAF/MEK molecular glue that holds RAF and MEK (MEK1/2) together, hitting several parts of the RAS/MAPK pathway at once. Its furthest stage is phase 1, for MAPK pathway-mutated or -dependent advanced solid tumours, melanoma, non-small cell lung cancer and glioma. ClinicalTrials.gov registers it in 2 studies linked below. Phase 1 NCT06326411 recruiting; an investigator-sponsored early phase 1 in recurrent grade 4 glioma (NCT07784985, Barrow Neurological Institute, Nested as collaborator) is not yet recruiting. Whether it works in people has not been established unless a trial below reports it.","status":"phase-1","asOf":"2026-11-03","links":[{"label":"Nested Therapeutics: nestedtx.com","url":"https://nestedtx.com/"},{"label":"Nested Therapeutics: nestedtx.com","url":"https://nestedtx.com/"},{"label":"Nested Therapeutics: clinicaltrials.gov","url":"https://clinicaltrials.gov/api/v2/studies/NCT06326411"},{"label":"Nested Therapeutics: clinicaltrials.gov","url":"https://clinicaltrials.gov/api/v2/studies/NCT07784985"},{"label":"ClinicalTrials.gov: trials of NST-628","url":"https://clinicaltrials.gov/search?intr=NST-628"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer","melanoma","nsclc","brain-tumours"],"sections":[],"technologies":[],"targets":["mek"],"drugs":[],"companies":["nested-therapeutics"],"institutions":[],"pathways":[],"terms":[],"trials":["nct06326411","nct07784985"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo gap audit, class 5 (company pipeline pages and ClinicalTrials.gov v2)","editedOn":"2026-11-03"},"code":"NST-628","modality":"Oral small-molecule molecular glue","mechanism":"A non-degrading, fully brain-penetrant pan-RAF/MEK molecular glue that holds RAF and MEK (MEK1/2) together, hitting several parts of the RAS/MAPK pathway at once.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/nst-628/","neighbours":{"cancer":[{"id":"brain-tumours","kind":"cancer","name":"Brain and spinal cord tumours (all types)","route":"/cancers/brain-tumours/"},{"id":"melanoma","kind":"cancer","name":"Melanoma","route":"/cancers/melanoma/"},{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"},{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"}],"target":[{"id":"mek","kind":"target","name":"MEK1/2","route":"/targets/mek/"}],"company":[{"id":"nested-therapeutics","kind":"company","name":"Nested Therapeutics","route":"/companies/nested-therapeutics/"}],"trial":[{"id":"nct07784985","kind":"trial","name":"A Study of NST-628 in Recurrent Grade 4 Glioma","route":"/trials/nct07784985/"},{"id":"nct06326411","kind":"trial","name":"A Study to Investigate the Safety and Efficacy of NST-628 Oral Tablets in Subjects With Solid Tumors","route":"/trials/nct06326411/"}]}}